Oral administration of penta-O-galloyl-β-d-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition

Carcinogenesis

Volumn 32, Issue 6, 2011, Pages 804-811

  Lee, Hyo Jeong ^a   Seo, Nam Jun ^a   Jeong, Soo Jin ^a   Park, Yongjin ^a   Jung, Deok Beom ^a   Koh, Wonil ^a   Lee, Hyo Jung ^a   Lee, Eun Ok ^a   Ahn, Kwang Seok ^a   Ahn, Kyoo Seok ^a   Lü, Junxuan ^b   Kim, Sung Hoon ^a,b  

^a Kyung Hee University   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GLUCOSE PENTAGALLATE; JANUS KINASE 1; KI 67 ANTIGEN; PACLITAXEL; PERVANADATE; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FEMALE; LUNG METASTASIS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT;

EID: 79958227890     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr015     Document Type: Article

References (27)

1. Jemal, A. et al. (2008) Cancer statistics, 2008. CA Cancer J. Clin., 58, 71-96.
2. Cleator, S. et al. (2007) Triple-negative breast cancer: therapeutic options. Lancet Oncol., 8, 235-244.
3. Irvin, W.J.Jr. et al. (2008) What is triple-negative breast cancer? Eur. J. Cancer., 44, 2799-2805.
4. =Rakha, E.A. et al. (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin. Cancer Res., 15, 2302-2310.
5. Visvader, J.E. et al. (2003) Transcriptional regulators in mammary gland development and cancer. Int. J. Biochem. Cell Biol., 35, 1034-1051.
6. Darnell, J.E.Jr. (2002) Transcription factors as targets for cancer therapy. Nat. Rev. Cancer., 2, 740-749.
7. Bharti, A.C. et al. (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol., 171, 3863-3871.
8. Buettner, R. et al. (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res., 8, 945-954.
9. Berishaj, M. et al. (2007) Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res., 9, R32.
10. Ihle, J.N. (1996) STATs: signal transducers and activators of transcription. Cell, 84, 331-334.
11. Ren, Z. et al. (2002) ErbB-2 activates Stat3 alpha in a Src- and JAK2-dependent manner. J. Biol. Chem., 277, 38486-38493.
12. Schreiner, S.J. et al. (2002) Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J. Biol. Chem., 277, 45680-45687.
13. Devarajan, E. et al. (2009) STAT3 as a central regulator of tumor metastases. Curr. Mol. Med., 9, 626-633.
14. Yu, H. et al. (2004) The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer., 4, 97-105.
15. Aggarwal, B.B. et al. (2006) Targeting signal-transducer-and-activator-oftranscription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci., 1091, 151-169.
16. Zhang, J. et al. (2009) Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucose. Pharm. Res., 26, 2066-2080.
17. Hu, H. et al. (2008) Penta-1, 2, 3, 4, 6-O-galloyl-beta-D-glucose induces p53 and inhibits STAT3 in prostate cancer cells in vitro and suppresses prostate xenograft tumor growth in vivo. Mol. Cancer Ther., 7, 2681-2691.
18. Huh, J.E. et al. (2005) Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways. Carcinogenesis, 26, 1436-1445.
19. Niu, G. et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 21, 2000-2008.
20. Kuo, P.T. et al. (2009) Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression. J. Agric. Food Chem., 57, 3331-3339.
21. Chai, Y. et al. (2010) Penta-O-galloyl-beta-D-glucose induces G1 arrest and DNA replicative S-phase arrest independently of cyclin-dependent kinase inhibitor 1A, P27 cyclin-dependent kinase inhibitor 1B and P53 in human breast cancer cells and is orally active against triple negative xenograft growth. Breast Cancer Res., 12, R67.
22. Li, L. et al. (2010) Preparation of penta-O-galloyl-beta-d-glucose from tannic acid and plasma pharmacokinetic analyses by liquid-liquid extraction and reverse-phase HPLC. J. Pharm. Biomed. Anal., 54, 545-550.
23. Li, L. et al. (2002) Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J. Biol. Chem., 277, 17397-17405.
24. Lieblein, J.C. et al. (2008) STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer, 8, 302.
25. Bittorf, T. et al. (1999) SHP1 protein tyrosine phosphatase negatively modulates erythroid differentiation and suppression of apoptosis in J2E erythroleukemic cells. Biol. Chem., 380, 1201-1209.
26. Hu, H. et al. (2009) Pentagalloylglucose induces autophagy and caspaseindependent programmed deaths in human PC-3 and mouse TRAMP-C2 prostate cancer cells. Mol. Cancer Ther., 8, 2833-2843.
27. Yu, H. et al. (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer., 9, 798-809.